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1. Introduction 
1.1 Epigenetics and cancer: An overview 
Genetic and epigenetic alterations are hallmarks of human cancer. In the last few decades, it 
has been well established that epigenetic changes are important events in human cancer 
development and progression in addition to genetic alterations (such as chromosomal 
rearrangements, aneuploidies and point mutations). Epigenetics refers to the study of 
changes in gene expression that are determined by mechanisms other than changes in the 
DNA sequence. Epigenetic phenomena include X-chromosome inactivation, genomic 
imprinting, cellular differentiation and the maintenance of cell identity. These events are 
mediated by several molecular mechanisms, including DNA methylation, post-translational 
histone modifications and various RNA-mediated processes. Many studies in the field of 
epigenetics have focused on the effects of histone modifications and DNA methylation in 
the transcription process because these mechanisms are often linked and interdependent 
(Ballestar, 2011). A variety of methods are currently being applied to detect epigenetic 
changes, and the past two decades have shown an exponential increase in novel approaches 
aimed at elucidating the molecular basis of epigenetic inheritance. 
DNA methylation is the most well studied epigenetic modification in human diseases 
(Fernandez et al., 2011). It involves the addition of a methyl group to the 5 carbon of a 
cytosine that is immediately followed by one guanine; i.e., DNA methylation typically 
occurs in a CpG dinucleotide context. CpG dinucleotides are generally underrepresented in 
the genome due to the increased mutation frequencies of the methylcytosines that are 
spontaneously converted to thymines. However, within the regions that are known as CpG 
islands, these dinucleotides are found at higher frequencies than is expected. It is believed 
that the human genome is comprised of approximately 38,000 CpG islands, and a large 
proportion of them (~37%) are located in the 5’ gene regulatory regions (promoters). The 
aberrant content of DNA methylation (global genome hypomethylation) and patterns of 
cytosine methylation, especially hypermethylation in promoter-associated CpG islands, are 
known to be associated with cancer. Gene-specific promoter hypermethylation causes the 
breakdown of normal cell physiology by silencing tumor suppressor genes, while DNA 
hypomethylation can reactivate oncogenes and repetitive sequences of the genome and lead 
to chromosomal instability (Sawan et al., 2008).  
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Histones (H2A, H2B, H3 and H4) are the main protein components of chromatin that 
package and order DNA into structural units that are called nucleosomes. The histone code 
consists of post-translational covalent changes of specific amino acid residues that are 
located at histone tails (NH2 terminal regions). These modifications include methylation, 
acetylation, phosphorylation, poly-ADP ribosylation, ubiquitinylation, sumoylation, 
carbonylation and glycosylation (Kouzarides, 2007). The histone code and DNA methylation 
interact to promote the regulation of specific gene activity and mediate chromatin 
accessibility and compaction by changing the local chromatin structure, as has been 
reported to occur during the silencing of tumor suppressor genes. In cancer cells, the 
hypermethylation of CpG islands in the promoter regions of tumor suppressor genes was 
associated with a specific profile of histone markers such as the loss of acetylation of 
histones H3 and H4, loss of H3K4 trimethylation, and gains of methylation  in lysine 
residues of histone H3 (such as H3K9 and H3K27) (Portela & Esteller, 2010). 
The most recently discovered epigenetic modification is mediated by a small class of RNAs 
that are also known as microRNAs (miRNAs). These molecules promote the silencing of 
target genes by associating with the 3’ untranslated region of messenger RNA (mRNA), 
which culminates in endonucleolytic cleavage, mRNA degradation by deadenylation or the 
inhibition of mRNA translation (Valeri et al., 2009). It is estimated that at least 30% of all 
human genes are regulated by miRNAs. Similar to the protein-coding genes, the down-
regulation of miRNAs in cancer cells has been correlated with the presence of DNA 
hypermethylation in the regulatory regions. In addition, these molecules (named epi-
miRNAs) were recently found to regulate epigenetic enzymes, such as DNA 
methyltransferases and histone deacetylases. Thus, it is possible that epi-miRNAs could 
indirectly affect the expression of cancer-related genes (Fabbri & Callin, 2010).  
In summary, epigenetics is one of the most promising fields in biomedical research. Novel 
strategies for risk assessment, early detection and new therapeutic targets may be revealed 
by epigenetic studies (Boumber & Issa, 2011). This chapter will summarize the common 
epigenetic aberrations that are detected in bladder cancer, their translational implications 
and possible epigenetic therapies. 
2. Translational implications of epigenetic changes in bladder cancer 
Bladder cancer is the fifth most commonly diagnosed non-cutaneous solid tumor and the 
second most common in the urological tract. Although many tumors that originate in this 
organ are superficial, with low risks of metastasis, bladder cancer has a high recurrence risk; 
the 4-year recurrence rate for patients with superficial tumors is 50%. Currently, the 
diagnosis of bladder cancer is based on histological, pathological and morphological 
parameters and provides only a generalized outcome for patients (Tanaka & Sonpadvde, 
2011). The gold standard for detecting bladder cancer is cystoscopic examination, but this 
analysis is costly, causes discomfort to the patient (invasive method) and has variable 
sensitivity, providing only a generalized outcome to patients. In addition, the sensitivity of 
the cytological analysis is questionable, especially in cases of low-grade carcinoma (Kim & 
Kim, 2009). With the advent of targeted therapy, molecular biomarkers are becoming 
increasingly important in both clinical research and practice. These markers are being 
identified with the purpose of reducing the need for invasive follow-up examinations and 
also to anticipate the prognosis of individual patients. Furthermore, the early diagnosis of 
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bladder cancer by non-invasive methods could allow for more effective treatment and 
optimize the success of surgical therapy.  
The DNA methylation of CpG islands that are mapped to promoter regions of specific 
genes, such as tumor suppressor genes, has been extensively reported in many cancer types. 
In bladder cancer, this epigenetic event has been related to tumor development, staging, 
recurrence, progression and clinical outcome. More specifically, DNA methylation has been 
strongly associated with higher stages, high rates of tumor progression and high mortality 
in patients with this cancer. As was demonstrated by Wolff et al. (2010), the analysis of 
epigenetic backgrounds can allow for the differentiation between noninvasive and invasive 
tumors by the identification of the different epigenetic characteristics that are present, such 
as the extensive DNA hypomethylation that is observed in noninvasive tumors compared to 
the high rates of DNA hypermethylation in invasive urothelial cancer. This may explain 
why ~15% of tumors will progress to invasive disease and have poor prognosis, while 
others will remain with low rates of generate metastasis.   
Currently, some histone modifications and the aberrant expression of miRNAs have been 
linked to tumorigenesis and have also been identified to be reliable and strong biomarkers 
for bladder cancer. MicroRNAs are specifically interesting because they are very stable in 
body fluids due to their small sizes and thus are resistant to degradation by nucleases, 
which are present in large quantities in urine (Tilki et al., 2011).     
2.1 Candidate epigenetic biomarkers in the diagnosis of bladder cancer 
Because DNA methylation is chemically and biologically stable and can be detected early in 
the carcinogenesis process, this epigenetic change has been considered to be a valuable 
potential diagnostic marker that is feasible to assess in clinical routine analysis through the 
investigation of exfoliated cells in the urine or blood of patients with bladder cancer and 
appears to be more sensitive than conventional cytology. A number of genes have been 
identified as being hypermethylated in the urine or tissue samples of cancer patients 
compared to healthy tissues, indicating that the down-regulation of these genes has some 
clinical relevance to the origin and development of the disease (Table 1).  
One example is the RUNX3 (runt-related transcription factor 3) gene, which has been 
mapped to 1p36 and is thought to be a tumor suppressor gene that is frequently deleted or 
transcriptionally silenced in patients with cancer. In a study that analyzed 124 tumor tissue 
samples, 73% were found to have a methylation-positive pattern compared to the 
methylation-free pattern that was exhibited by the normal bladder mucosa. Moreover, the 
methylation of this gene was found to confer a significant increase (100-fold) in the risk of 
tumor development (Kim et al., 2005), suggesting that it may have potential as a potent 
bladder cancer detection marker. 
Our group also contributed to the literature surrounding epigenetic markers in bladder 
cancer. We discovered high rates of DNA methylation in exfoliated urinary cells, in which 
the RARB gene had a sensitivity of 95% and specificity of 71% for detecting the presence of 
cancer (Negraes et al., 2008). These results are concordant with the increased methylation 
frequencies that have been previously described (Chan et al., 2002; Hoque et al., 2006) and 
suggest that this gene could be considered as a diagnostic biomarker. It encodes a member 
of the thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators 
that binds retinoic acid (the biologically active form of vitamin A) and also mediates cellular 
signaling during embryonic morphogenesis and cell growth and differentiation. It is 
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thought that this protein limits the growth of many cell types by regulating gene expression 
(Soprano et al., 2004).  
In the study conducted by Renard et al. (2010), it was demonstrated that 2 genes (TWIST1 
and NID2) were frequently methylated in urine samples collected from bladder cancer 
patients, including those with early-stage and low-grade diseases, with a specificity of 93% 
and sensitivity of 90%, which was an improvement from the cytological method of detection 
(48%). 
Besides the identification of DNA hypermethylation at a single locus, some authors have 
demonstrated that several genes may be analyzed together to generate a profile of 
hypermethylated genes.  These profiles may be able to allow for a more sensitive and 
reliable marker for the detection of bladder cancer (Table 1). Based on this, Chan et al. (2002) 
discovered that the sensitivity of the methylation analysis (90.9%) of four genes (DAPK1, 
RARB, CDH1 and CDKN2A) was higher than that of urine cytology (45.5%) for cancer 
detection and was more striking in low-grade cases (100% versus 11.1%).  
Similarly, Urakami et al. (2006) found that the identification of the increased methylation of 
six Wnt-antagonist genes (SFRP1, SFRP2, SFRP4, SFRP5, WIF1 and DKK3) could predict 
bladder tumors with a sensitivity of 77.2% and specificity of 66.7%. These genes are known 
to inhibit Wnt signaling by binding to specific molecules that act in this pathway. The DNA 
methylation and consequent functional loss of these genes may result in the activation of the 
Wnt signaling pathway and promote the dysregulation of cell proliferation and 
differentiation. The authors also discovered that two of these genes (SFRP2 and DKK3) were 
able to act as independent predictors of bladder tumors (P < 0.05 and P < 0.01, respectively). 
Friedrich et al. (2004) also suggested that the presence of a combination of DNA methylation 
at the 5’ regions of three apoptosis-associated genes (DAPK1, BCL2 and TERT) in urine 
sediment could be diagnostic of bladder cancer with a sensitivity of 78%, suggesting that 
this combined methylation analysis was a highly sensitive method for the noninvasive 
detection of bladder cancer.      
In addition, Hoque et al. (2006) proposed a two-stage predictor for the classification of 
bladder cancer that was based on an investigation of a panel composed of nine genes 
(APC, ARF, CDH1, GSTP1, MGMT, CDKN2A, RARB, RASSF1A and TIMP3) in urine 
sediment. In the first stage, patients who presented with DNA methylation in the 
promoters of at least one of four specific genes (CDKN2A, ARF, MGMT and GSTP1) were 
classified as having cancer (100% specificity). Moreover, patients with no methylation in 
these genes were subjected to a second stage of investigation with a logistic prediction of 
risk scores based on the promoter methylation of the five remaining genes (sensitivity of 
82% and specificity of 96%). 
Three of these genes had previously been investigated by Dulaimi et al. (2004), who 
demonstrated the feasibility of obtaining reproducible highly sensitive (87%) and 100% 
positive identifications of hypermethylation in a panel composed of the APC, RASSF1A and 
CDKN2A tumor suppressor genes in urine in cases of early-stage disease. In addition to 
RASSF1A (a tumor suppressor gene that is frequently inactivated in several cancer types), 
the other two genes chosen were involved in the p53/p14ARF tumor suppressor gene pathway 
(CDKN2A gene) (Sherr & McCormick, 2002) and the Wnt signaling pathway (APC gene) 
(Taipale & Beachy, 2001). The evaluation of this panel yielded superior results compared to 
those of cytology in the detection of bladder cancer. Yates et al. (2006) also investigated the 
APC, RASSF1A and CDH1 genes in urine. This panel generated a lower sensitivity (69%) 
and specificity (60%) than the former; however, the diagnostic accuracy was 86%. 
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Many of the genes that have been chosen to be investigated in combined analyses to 
generate panels have frequently been suggested to be individually methylated in bladder 
cancer, such as RASSF1A. The DNA methylation of this gene had previously been reported 
to be able to detect bladder cancer in urine samples with 100% sensitivity by Chan et al. 
(2003). The authors advocated that the detection of gene methylation using multiple markers 
could increase both the sensitivity and specificity of cancer detection, and the addition of 
RASSF1A to this panel could improve the diagnostic accuracy even further. 
Yu et al. (2007) discovered that the methylation of a panel composed by 11 genes (SALL3, 
CFTR, ABCC6, HPSE, RASSF1A, MT1A, ALX4, CDH13, RPRM, APBA1 and BRCA1) in urine 
sediments showed positive correlations with  diagnosis in 121 out of 132 bladder cancer 
cases with a sensitivity of 91.7% and accuracy of 87%. Remarkably, this approach was able 
to detect more than 75% of tumors at stage 0a and 88% of stage I tumors, indicating the 
value of this panel in the early diagnosis of bladder cancer.   
Likewise, a three-gene (GDF15, TMEFF2 and VIM) panel was able to detect bladder cancer 
in urine samples with a sensitivity of 94% and specificity of 100% (Costa et al., 2010), 
exceeding the detection rates that are normally obtained using conventional cytopathology 
and cytology. This panel of genes was selected based on stringent criteria after a screening 
test that employed a genome-wide approach and was distinctive because it was able to 
detect bladder cancer by noninvasive methods even when patients with kidney or prostate 
cancer were used as controls. These three genes are biologically relevant to carcinogenesis 
because TMEFF2 (mapped at 2q32.3) and VIM (mapped at 10p13) were previously found to 
be silenced by promoter methylation in esophageal, colorectal (Shirahata et al., 2009; 
Tsunoda et al., 2009) and bladder cancer (Hellwinkel et al., 2008). GDF15 (mapped to 
19p13.11) is a member of the transforming growth factor (TGF)-β superfamily and may act 
as a tumor suppressor gene in early-stage cancers (Eling et al., 2006). 
Another biomarker of interest for the detection of urothelial cancer, according to Ellinger et 
al. (2008), is cell-free serum DNA methylation. The authors detected that the diagnostic 
accuracy of this marker increased when hypermethylation at multiple gene sites was 
assessed simultaneously, particularly at the GSTP1, RARRES1 or APC genes (80% sensitivity 
and 93% specificity).  
The list of aberrant epigenetically regulated genes continues to grow. Is important to note 
that the same genes have been investigated by different groups, and the methylation rates 
found may vary from one report to another. Results may reflect the distinct methodologies 
employed, the numbers and types of samples (urine, surgical tissue and/or serum) as well 
as disease classifications. Nevertheless, the reports above highlight the high potential of 
DNA methylation markers for the effective early detection of bladder cancer using 
noninvasive urine tests. 
The measurement of global cytosine methylation rates (%5-mC) concomitantly with the 
DNA methylation of specific genes could be a useful biomarker to assess a patient’s 
susceptibility to bladder cancer. In a large case-control study conducted by Moore et al. 
(2008), the DNA hypomethylation of leukocytes was strongly associated with an increased 
bladder cancer risk, and this association was independent of smoking and other assessed 
risk factors.  
Recently, evidence has emerged that circulating miRNAs are present in human body fluids 
(as urine) in concentrations that are subject to variation during cancer pathogenesis or 
development (Iguchi et al., 2010), as was reported by Dudziec et al. (2011). The authors 
discovered that the combined low expression levels of miR-152, -328 and -1224-3p allowed 
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for accurate diagnosis with 81% sensitivity and 75% specificity. These miRNAs were found 
to be epigenetically regulated by DNA methylation at CpG islands and the shores (regions 
of less dense CpG dinucleotides) that surrounded them following a genome-wide screening. 
In addition, Hanke et al. (2010) found that the ratio of miR-126:miR-152 enabled the 
detection of bladder cancer from urine samples with a specificity of 82% and a sensitivity of 
72%; thus, they may be used as a tumor markers for this disease.  
In addition, Yamada et al. (2011) identified one microRNA (miR-96) that may be a useful 
diagnostic marker with high sensitivity and specificity (71.0% and 89.2%, respectively) when 
assessed in combination with urinary cytology (80% diagnostic accuracy). This molecule, 
which has been mapped to 7q32, is a putative onco-miRNA that has been demonstrated to 
be able to down-regulate tumor suppressor genes. It was found to be up-regulated in a 
previous study conducted by the same group (Ichimi et al., 2009), in which the microRNA 
expression signatures that are specific to bladder cancer were determined, and a subset of 7 
microRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) 
that are significantly down-regulated in bladder cancer were validated. These microRNAs 
were sufficiently sensitive (>70%) and specific (>75%) to distinguish bladder cancer from 
normal epithelium.  
As mentioned above, not only the DNA methylation but also the expression profile of the 
miRNA molecules have been closely associated with the diagnosis of bladder cancer. 
 
Epigenetic biomarker Samples 
Sensitivity/ specificity/ 
OR 
Supporting 
literature 
DNA methylation 
RASSF1A Urine Sensitivity: 100% Chan et al., 2003 
RUNX3 Tissue 
OR 107.55 (95% CI, 6.33-
1827.39) 
Kim et al.,  
2005 
RARB 
Bladder 
washing 
(exfoliated 
cells) 
OR/Sensitivity/specificity: 
48.89/95%/71% 
Negraes et al., 
2008 
TWIST1 and NID2 Urine 
Sensitivity/specificity: 
90%/93% 
Renard et a., 
2010 
DAPK1, RARB, CDH1
and CDKN2A 
Urine 
Sensitivity/specificity: 
90.9%/76.4% 
Chan et al.,  
2002 
APC, RASSF1A and 
CDKN2A 
Urine 
Sensitivity/specificity: 
87%/100% 
Dulaimi et al., 
2004 
DAPK1, BCL2 and 
TERT 
Urine Sensitivity: 78% 
Friedrich et al., 
2004 
APC, ARF, CDH1, 
GSTP1, MGMT, 
CDKN2A, RARB, 
RASSF1A and TIMP3 
Urine 
1st stage 
  sensitivity: 100% 
2nd stage 
  Sensitivity/specificity: 
82%/96% 
Hoque et al., 
2006 
SFRP1, SFRP2, SFRP4, 
SFRP5, WIF1, DKK3  Tissue 
Sensitivity/specificity: 
77.2%/66.7% 
Urakami et al., 
2006 
APC, RASSF1A and Urine Sensitivity/specificity: Yates et al., 2006 
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Epigenetic biomarker Samples 
Sensitivity/ specificity/ 
OR 
Supporting 
literature 
CDH1 69%/60%  
SALL3, CFTR, ABCC6, 
HPSE, RASSF1A, 
MT1A, ALX4, CDH13, 
RPRM, APBA1 and 
BRCA1 
Urine 
Sensitivity/especificity: 
91.7%/87% 
Yu et al.,  
2007 
GSTP1, RARRES1, APC 
Cell-free 
serum DNA 
Sensitivity/specificity: 
80%/93% 
Ellinger et al., 
2008 
GDF15, TMEFF2 and 
VIM 
Urine 
Sensitivity/specificity: 
94%/100% 
Costa et al.,  
2010 
%5-mC of leukocytes Blood cells 
OR 1.38 (95% CI:1.05–1.08, 
p=0.02) 
Moore et al., 
2008 
miRNAs 
miR-145, miR-30a-3p, 
miR-133a, miR-133b, 
miR-195, miR-125b and 
miR-199a* 
Tissue 
Sensitivity/specificity: 
>70%/>75% 
Ichimi et al.,  
2009 
RNA ratio of miR-
126:miR-152 
Urine 
Sensitivity/specificity: 
72%/82% 
Hanke et al., 
2010 
miR-152, -328 and -1224 Urine 
Sensitivity/specificity: 
81%/75% 
Dudziec et al., 
2011 
miR-96 Urine 
Sensitivity/specificity: 
71%/89.2% 
Yamada et al., 
2011 
Table 1. Epigenetic diagnostic markers in bladder cancer. The genes were described as 
official symbols according recommendations of Guidelines for Human Gene Nomenclature. 
More information about specific genes can be achieved at 
http://www.genenames.org/guidelines.html. 
2.2 Candidate epigenetic biomarkers in the prognosis of bladder cancer 
The knowledge of prognostic factors is of great importance for the determination of 
therapeutic strategies and to enable the application of different modalities of therapy in 
cancer treatment. In cases of bladder cancer, patients are monitored for recurrence or 
progression by periodic cystoscopy and urine cytological analysis, the frequencies of which 
vary depending on the risk factors that are associated with the disease. Thus, the discovery 
of more sensitive and non-invasive tumor markers that can help to predict tumor 
recurrence, progression and metastasis are required, and epigenetic alterations may be 
promising new potential prognostic markers for bladder cancer. 
Bladder tumors may be superficial, with low risks of metastasis, but may have high 
recurrence risks (McConkey et al., 2010). Several genes that are related to the progression 
and prognosis of bladder cancer have been identified in bladder washes, urine and tumor 
tissues using various molecular and epigenetic approaches (Mitra et al., 2006) and are 
considered to be potential markers (Table 2).  
Maruyama et al. (2001) determined the methylation statuses of 10 genes in 98 fresh bladder 
tumor tissues and found that multiple genes are methylated during the process of bladder 
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cancer development. Their results also indicated that the frequent methylation of four genes 
(CDH1, CDH13, RASSF1A and APC) together with high MIs (median methylation index) 
were correlated with poor prognosis (tumors showed high grade, nonpapillary growth 
patterns, muscle invasions, advanced tumor stages and aneuploidies). In addition, the 
methylation of CDH1, FHIT and high MIs were associated with reduced patient survival 
rates. 
In a study performed by Catto et al. (2005) that employed a large cohort of urothelial 
carcinomas, CpG hypermethylation at DAPK was associated with higher progression rates 
(log-rank P = .014) in all of the transitional-cell carcinoma (TCC) samples that were 
investigated compared to unmethylated samples at this locus. 
In another study, Christoph et al. (2006) selected related genes as targets of p53 in the 
apoptotic cycle to perform a quantitative analysis of 110 tumor samples. The authors found 
that APAF1 methylation levels were correlated with tumor stages and grades. In addition, 
the methylation levels of the APAF1 and IGFBP3 genes enabled tumors with higher 
recurrence risks to be distinguished from low-risk tumors in non-muscle-invasive and 
muscle-invasive tumors. The epigenetic inactivation of pro-apoptotic genes may be 
important events that are related to the progression and increased aggressiveness of tumors 
that are hypermethylated in these loci. 
In addition, the hypermethylation of the promoter region of the TIMP3 gene detected in 
urine sediments was found to be associated with an increased risk of death (Hoque et al., 
2008). Other genes also have been found to undergo aberrant promoter methylation and 
were associated with poor prognosis in bladder cancer, including the hypermethylation of 
the RUNX3 promoter, which was correlated with the development of invasive tumors, 
tumor progression and cancer specific-survival in patients with TCC (Kim et al., 2008).  The 
methylation of this gene was also shown to be related to an increased risk of developing 
bladder cancer (Kim et al., 2005), suggesting that this gene not only suppresses the 
aggressiveness of tumors but also inhibits the tumor development. 
Beyond to the tumor size and grade parameters, response to treatment is also an important 
prognostic factor because multidrug resistance to chemotherapy is a major obstacle in the 
treatment of cancer patients. Tada et al. (2000) showed that the overexpression of the ABCB1 
gene may be a prognostic factor indicating recurrence in bladder cancer, and the 
hypomethylation of the promoter of this gene may be necessary for the development of 
increased ABCB1 mRNA levels and multidrug resistance. 
Global DNA hypomethylation is also a common phenomenon that has been reported in 
bladder cancer (Seifert et al., 2007). The loss of DNA methylation in repetitive sequences 
may account for a majority of the global hypomethylation that characterizes a large 
percentage of human cancers. Neuhausen et al. (2006) found that the hypomethylation of 
LINE-1 retrotransposons was present in 90% of the urothelial carcinoma specimens that 
were studied, and the absence of this epigenetic change was indicative of a better clinical 
prognosis. In a high-throughput DNA methylation analysis, a distinct hypomethylation 
pattern was found in non-invasive (Ta-T1) urothelial tumors compared to both normal 
urothelium and invasive tumors (Wolff et al., 2010). These researchers found a substantial 
number of probes to be hypomethylated in non-invasive tumors only, suggesting that lower 
levels of DNA methylation may be related to a less malignant phenotype. 
A particularly interesting example of epigenetic regulation is genomic imprinting, in which 
one copy of a gene is silenced in a manner determined by its parental origin. Thus, 
imprinted genes show parental-specific monoallelic expression. The loss of allele-specific 
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expression pattern is termed as loss of imprinting (LOI), an event described in several types 
of pediatric and adult cancers (Monk, 2010).  LOI has already been identified as an 
 
Clinical – 
histolopathological 
parameters 
Epigenetic biomarker Supporting literature 
Grade 
DNA methylation 
CDKN2A, BCL2, TERT, 
EDNRB, CDH1, RASSF1A, 
APC, CDH13 
Maruyama et al., 2001; 
Domínguez et al.,  2002; 
Friedrich et al., 2004 
Stage 
DNA methylation 
TIMP3, CDKN2A, RASSF1A, 
BCL2, OPCML, CDH1, APC, 
CDH13 
Histone modification 
H4K20me1 
Maruyama et al., 2001; 
Domínguez et al.,  2002; 
Friedrich et al., 2004; Hoque et 
al., 2008; Schneider et al. 2011; 
Duarte-Pereira et al., 2011 
Recurrence 
DNA methylation 
DAPK1, H19, TIMP3 
Ariel et al., 2000; Tada et al., 
2002; Friedrich et al., 2005 
Survival 
DNA methylation 
TIMP3, OPCML, RUNX3, 
FHIT, CDH1 
Histone modification 
H4K20me3 
Maruyama et al., 2001; Kim et 
al., 2008; Hoque et al., 2008; 
Schneider et al. 2011; Duarte-
Pereira et al., 2011 
Metastasis 
DNA methylation 
TIMP3 
miRNA expression 
miR-452, miR-452* 
Hoque et al., 2008; Veerla et al., 
2009 
Muscle invasion 
DNA methylation 
CDKN2A, CDH1, RASSF1A, 
APC, CDH13 
miRNA expression 
miR-222, miR-125b 
Maruyama et al., 2001; 
Domínguez et al.,  2002; Veerla 
et al., 2009 
Tumor progression 
DNA methylation
RASSF1A, CDH1, TNFRSF25, 
EDNRB, APC, DAPK1, H19 
Histone modification 
H3K4me1, H4K20me1, 
H4K20me2, H4K20me3 
miRNA expression 
Set of miR-21, miR-510, miR-
492, miR-20a, miR-198 and set 
of miR-455-5p, miR-143, miR-
145, miR-125b, miR-503 
Catto et al., 2005; Yates et al., 
2007; Dyrskjøt et al., 2009; 
Schneider et al. 2011 
Table 2. Epigenetic prognostic markers in bladder cancer. The genes were described as 
official symbols according recommendations of Guidelines for Human Gene Nomenclature. 
More information about specific genes can be achieved at 
http://www.genenames.org/guidelines.html. 
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epimarker of cancer development. The IGF2 and H19 imprinted genes have been well 
documented in the literature. Some studies showed that the H19 gene is involved in the 
development of bladder cancer (Ariel et al., 1995; Elkin et al., 1995) and is associated with 
high recurrence risks for this tumor type (Ariel et al., 2000). Furthermore, insulin-like 
growth factor-II (IGF-II) loss of imprinting (LOI) in a series of paired tumoral and normal 
adjacent bladder tissues and E-cadherin (CDH1) immunolocalization suggested a possible 
mechanism underlying E-cadherin relocalization to the cytoplasm, that is, the presence of 
aberrant levels of IGF-II due in some cases to IGF2 LOI (Gallagher et al., 2008). Furthermore, 
the finding of LOI in the tumoral adjacent normal samples holds promise of IGF2 LOI as a 
predictor of tumor development.  
Others epigenetic mechanisms in cancer patients remain less comprehensively understood. 
One of these epigenetic changes involves the histone modifications, which include changes 
in their levels and distribution at gene promoters, gene coding regions, repetitive DNA 
sequences and other genomic elements (Kurdistani, 2011). In a recent study, Schneider et al. 
(2011) found that global levels of H3K4me1, H4K20me1, H4K20me2 and H4K20me3 were 
decreased compared to normal urothelium. The distribution of these histone modifications 
were associated with the risk of metastasis in muscle-invasive compared to non-muscle-
invasive bladder cancers. The authors also showed that H4K20me1 levels were increased in 
patients with non-muscle-invasive bladder cancer with advanced pT stages and less 
differentiated bladder cancer, and H4K20me3 levels were significantly correlated with 
mortality after radical cystectomy in patients with muscle-invasive cancer.  
Recently, several groups have questioned whether the miRNA expression profiles or even 
single miRNAs could act as useful biomarkers not only for cancer diagnosis but also for 
prognosis and treatment optimization (Lu et al., 2005; Calin & Croce, 2006). Dyrskjøt et al. 
(2009) identified the aberrant expression of several miRNAs in 106 samples from patients 
with different stages of bladder cancer and associated their profiles with disease 
progression. Among the miRNAs that were differentially expressed in normal bladder 
tissue compared to that of bladder cancer, two subsets [(miR-21, miR-510, miR-492, miR-20a, 
miR-198) and (miR-455-5p, miR-143, miR-145, miR-125b, miR-503)] were up- and down-
regulated by two-fold, respectively. In another large-scale study that evaluated miRNA 
expression, high expression levels of miR-222 and miR-125b were observed in muscle-
invasive tumors, and miR-452 and miR-452* were shown to be over-expressed in node-
positive tumors (Veerla et al., 2009).  
Moreover, aberrant DNA methylation has been implicated in the deregulation of several 
miRNAs in different types of cancer (Lujambio et al., 2007). Wiklund et al. (2011) studied 
this relationship and found that the miR-200 family and miR-205 are concurrently silenced 
and that DNA hypermethylation would be associated with the silencing of these 
microRNAs in invasive bladder tumors. They also found that the loss of miR-200c 
expression was associated with disease progression of muscle-invasive cancers and with 
poor prognosis. 
3. The promise of epigenetic therapy 
The knowledge of epigenetic alterations that are associated with human cancers and their 
potential reversibility has prompted the development of drugs that target epigenetic 
enzymes. Either natural or synthetic modulators can be utilized to restore normal epigenetic 
and gene expression patterns; for example, by restoring the expression of the frequently 
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silenced RUNX3 gene, which is considered to be good target for this new therapeutic 
modality since the loss of its function in cancer cells due to genetic mutations is a rare event 
(Kim et al., 2005). The epigenetic therapy can be used alone or in combination with other 
therapeutic modalities, such as chemotherapy, immunotherapy or radiotherapy. This 
approach will eventually lead to targeted therapies that are suited for specific molecular 
defects, thereby significantly decreasing the morbidity associated with bladder cancer in 
addition to other cancers (Balmain, 2002; Kim & Kim, 2009; Mund & Lyko, 2010). 
Two principal classes of epigenetic drugs have been demonstrated to be clinically relevant: 
DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors 
(Esteller, 2005) (Table 3). Novel epigenetic compounds that are of potential interest as 
clinical therapeutic drugs include the histone acetyltransferase inhibitors, such as anacardic 
acid, curcumin and peptide CoA conjugates. In addition, histone methyltransferase 
inhibitors and HDACis  that are specific for SIRT1 (class III HDAC), such as nicotinamide 
and splitomycin, are now under intense analysis (Ballestar & Esteller, 2008; Greiner et al., 
2005). 
3.1 DNMTs inhibitors 
Genes that are silenced by DNA hypermethylation may be reactivated by small molecules 
that are called DNMT inhibitors. These agents may be structural analogues of the nucleoside 
deoxycytidine or non-nucleoside analogues. The analogues, after being phosphorylated by 
kinases that convert the nucleosides into nucleotides, can be incorporated into DNA and 
subsequently inhibit DNMT activity by forming a covalent bond with the cysteine residue in 
the active DNMT site. However, it has also been shown that such incorporation may lead to 
instabilities in DNA structure and even DNA damage (Bouchard & Momparler, 1983; Goffin 
& Eisenhauer, 2002). 
Two prominent examples are the cytosine analogs 5-azacytidine (azacytidine, Vidaza) and 
2’-deoxy-5-azacytidine (decitabine, Dacogen), which are potent inhibitors of DNMTs (Table 
3) and have been approved by the FDA (Food and Drug Administration) for the treatment 
of myelodysplastic syndrome, a pre-leukemic bone marrow disorder (Lübbert, 2000). 
Various additional molecules has been found to possess better stability and less toxicity and 
are currently being investigated as DNMT inhibitors in preclinical experiments, such as 
dihydro-5-azacytidine, arabinofuranosyl-5-azacytosine (fazarabine) and zebularine (Cheng 
et al., 2003).  
Azacytidine and decitabine have been widely used in cell culture systems to reverse DNA 
hypermethylation and restore silenced gene expression. However, results from in vivo 
studies are not satisfactory, especially with solid tumors in which limited efficacy has been 
encountered. In general, both agents are unstable in aqueous solutions, have short half-lives 
and need to be freshly prepared before administration. In addition, both drugs have 
relatively poor bioavailabilities and high cytotoxic effects with potential risks, such as 
myelotoxicity, mutagenesis, and tumorigenesis, which have limited their clinical 
applications (Jackson-Grusby et al., 2007). 
Despite this discouraging data, the orally administered zebularine shows some promise. It 
was shown to suppress the growth of TCC in bladder xenografts in nude mice and was less 
toxic than other nucleoside analogues. In addition, when zebularine was given at a lower 
dose after an initial dose of decitabine, a profound demethylation of the CDKN2A gene 
promoter was observed. These results provide a rationale for the strategy of combining an 
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initial administration of a parenteral DNMT inhibitor with a subsequent low dose of oral 
zebularine (Cheng et al., 2004; Zhang et al., 2006).  
Another group of compounds are called non-nucleoside analogues. These small molecules 
inhibit DNA methylation by binding directly to the catalytic site of the DNMT enzyme 
without being incorporated into the DNA. The local anesthetic procaine and its derivative 
procainamide, which is an approved antiarrhythmic drug, have exhibited demethylating 
activities. For example, Lin et al. (2001) reported that procainamide was able to restore 
GSTP1 gene expression by reversing the hypermethylation of the promoter CpG islands of 
androgen-sensitive human prostate adenocarcinoma (LNCaP) cells in vitro and in vivo. 
Because these agents do not incorporate into DNA, it is expected that they may have less 
genotoxicity than nucleoside DNMT inhibitors. In addition, (-)-epigallocatechin-3-gallate 
(EGCG), the main polyphenol compound in green tea, also acts as DNMT inhibitor . Cancer 
cells treated with micromolar concentrations of EGCG showed reduced DNA methylation 
and the increased transcription of tumor suppressor genes. However, it is still unknown 
whether EGCG has a direct inhibitory effect on DNMTs (Fang et al., 2003; Villar-Garea et al., 
2003). 
3.2 HDAC inhibitors 
A variety of structurally distinct groups of compounds have been identified as histone 
deacetylase inhibitors (HDACi) (Table 3). These compounds inhibit histone deacetylase 
activity by binding to the catalytic site of the enzyme and chelating zinc ions because they 
share similar structures with the substrates (Finnin et al., 1999). Similar to their effects on 
gene expression and differentiation, HDACi have also been shown to be efficient inducers of 
apoptosis in several cellular systems. The precise mechanism of this effect is under 
investigation, and it has been suggested that they may affect cellular oxidative stress and 
DNA damage induction. They have shown impressive activities in preclinical studies as 
well as selectivity for neoplastic cells.  Many HDACi are being tested in clinical trials for 
various malignancies (Bolden et al., 2006; Xu et al., 2007).  
The class of the HDAC inhibitors is divided into four groups: hydroxamic acids, cyclic 
tetrapeptides, short-chain fatty acids and benzamides. The hydroxamate compounds are 
more potent and have higher inhibitory effects. Trichostatin A from Streptomyces 
hygroscopicus is active at nanomolar concentrations, while the synthetic compounds, such 
as suberoylanilide hydroxamic acid (SAHA), can function in low micromolar or 
nanomolar ranges. Cyclic tetrapeptides are very potent compounds and can inhibit 
histone deacetylase at nanomolar concentrations. Short-chain fatty acid compounds 
usually require millimolar concentrations to inhibit histone deacetylase activities in vivo; 
therefore, their clinical applicability could be limited. The fourth class is the benzamides, 
such as MS-275 and CI-994, which are effective at micromolar concentrations (Rosato et 
al., 2003; Zhang et al., 2006). 
The clinical potentials of histone deacetylase inhibitors have been suggested by several 
promising in vivo studies. For example, SAHA was FDA approved in Oct. 2006 for the 
treatment of cutaneous T cell lymphoma (CTCL), and it is under a phase I clinical trial for 
use in patients with TCC (Mann et al., 2007). Preliminary reports have indicated that 2 out of 
6 patients with metastatic TCC disease have had objective tumor regression and tumor-
related symptom relief (Kelly et al., 2003). The induction of CDKN1A messenger RNA and 
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Group Drug Clinical status 
DNMT inhibitor
Nucleoside 
analogues 
5-Azacyticine Approved 2004 for MDS 
2´-Deoxy-5-
azacytidine 
Approved 2006 for MDS 
Zebularine Preclinical 
Non-
nucleoside 
analogues 
Hydralazine Phase I > II for cervical Ca 
MG98  Phase I > II for advanced metastatic tumors 
Procaine Preclinical 
RNAi Preclinical 
Epigallocatichin-3-
gallate  
Preclinical 
Psammaplin A Preclinical 
HDAC  inhibitor
Hydroxamic 
acids 
Suberoylanilide 
hydroxamic acid 
(SAHA) 
Approved 2006 for CTCL 
Panobinostat 
Phase I > II > III  for breast Ca, gliomas, prostate 
Ca, NSCLC, CTCL, leukemia 
Belinostat 
Phase I > II for ovarian Ca, CTCL, lymphoma, 
multiple myeloma, leukemia 
Trichostatin A Preclinical 
Cyclic 
tetrapeptides 
Depsipeptide, 
Romidepsin 
Approved 2009 for CTCL 
Short-chain 
fatty acids 
Valproic acid 
Phase I > II > III  for melanoma, myelodysplastic 
syndrome, leukemia, chronic lymphocytic 
leukemia, cervical Ca, breast Ca 
AN-9 
Phase I > II for malignant melanoma, leukemia, 
lymphoma, NSCLC  
Benzamides 
Entinostat 
Phase I > II for breast Ca, acute lymphoblastic 
leukemia, Hodgkin’s lymphoma, MDS, renal Ca, 
colorectal Ca, lung Ca 
Mocetinostat 
Phase I > II for breast Ca, NSCLC, prostate Ca, 
stomach Ca, non-Hodgkin’s lymphoma, 
Hodgkin’s lymphoma, AML, CLL, lymphoma 
N-Acetyldinaline 
Phase I > II > III  for multiple myeloma, lung Ca, 
pancreatic Ca 
Table 3. List of the main DNMT and HDAC inhibitors and their current clinical trial status. 
MDS: myelodysplastic syndrome, CTCL: cutaneous T cell lymphoma, NSCLC: non small 
cell lung cancer, AML: acute myeloid leukemia, CLL: Chronic lymphocytic leukemia, Ca: 
cancer. Clinical status source: clinicaltrials.gov. 
protein levels in T24 cells following SAHA exposure mediated by increased acetyl H3 and 
H4 levels in the respective promoter region may contribute to its tumor inhibitory effect 
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(Richon et al., 2000). Other researchers have reported similar inhibitory effects on bladder 
tumor growth using trichostatin A and pyroxamide on T24 cells. Additionally, trichostatin 
A is able to suppress 70% of tumor growth with no detectable toxicity in EJ and UM-UC-3 
xenograft models (Canes et al., 2005).  
3.3 Combination therapy 
The emerging concept of gene silencing involves the interaction of multiple factors that may 
act in a sequential manner. It is also known that a single agent may not be able to eradicate a 
tumor mass that is derived from a very heterogeneous population of cells. Moreover, the 
adverse toxic effects that are caused by single-agent treatments, especially at high doses, call 
for a rationalized therapeutic approach with low-dosage drug combinations. Accumulating 
evidence has shown that the combination of histone deacetylase inhibitors and DNMT 
inhibitors is very effective (and synergistic) in inducing apoptosis, differentiation and/or 
cell growth arrest in various human cancer cell lines (Gottlicher et al., 2001; Mei et al., 2004; 
Stirzaker et al., 2004).  
In urologic cancers, Cameron et al. (1999) showed that the combination of decitabine and 
trichostatin A stimulated a synergistic reactivation of several tumor suppressor genes. Dunn 
et al. (2005) reported that the combination of DNMT inhibitors and histone deacetylase 
inhibitors was able to reactivate the sensitivities of LNCaP cells to interferon treatment by 
the re-expression of JAK1 kinase, which is a key mediator of both interferon-gamma and 
interferon-alpha/beta receptor-elicited effects. Another strategy is to combine either histone 
deacetylase inhibitors or DNMT inhibitors with conventional therapies, as was 
demonstrated by Zhang et al. (2007), who indicated that the combination of FK228 (a HDAC 
inhibitor) and docetaxel (chemotherapeutic drug) caused a synergistic growth inhibition in 
androgen-independent prostate cancer cell lines. Moreover, single treatments with SAHA or 
MS-275 show enhanced radiation-induced cytotoxicity in DU-145 cells both in vitro and in 
vivo (Chinnaiyan et al., 2005). 
4. Future 
There is a great deal of evidence that demonstrates the connections between epigenetic 
modification enzymes and cancer. Epigenetic alterations contribute to tumorigenesis by the 
activation of oncogenes or inactivation of tumor suppressor genes. The identification of 
molecules that can modulate epigenetic enzymes could lead to the prevention of oncogene 
transcription and activation of tumor repressors, and thus it is an important topic to 
research (Zheng, 2008). 
A major impediment to the use of such drugs is that they are nonspecific and may reactivate 
genes non-discriminately. However, this does not seem to be a problem in the present case 
because DNA methylation inhibitors only act on dividing cells and leave normal, non-
dividing cells unaffected. Also, it seems that the drugs preferentially activate genes that 
have become abnormally silenced in cancer. Further studies are required to establish an 
unambiguous proof of concept for epigenetic cancer therapies (Jones & Baylin, 2007; Liang 
et al., 2002; Mund & Lyko, 2010).  
For future clinical applications, researchers should focus on several aspects, including the 
biomarkers that predict drug responses. Researchers should also focus on the screening of 
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new, more effective and less toxic agents. The psammaplin, for example, a family of 
bromotyrosine derivatives that have been extracted from the marine sponge Pseudoceratina 
purpurea, appear to be a novel class of compounds with the ability to inhibit both DNMT 
and histone deacetylase activities (Pina et al., 2003).  
In addition, exploring the silencing of specific genes by RNA interference for key epigenetic 
regulatory complexes could enhance therapeutic indices. For example, DNMT-specific 
siRNA (single-interfering RNA) is able to elicit the demethylation of several epigenetically 
silenced genes. Additionally, the treatment of cultured cells in vivo with demethylating 
agents, either alone or in combination with HDACi, has been shown to re-activate the 
expression of tumor-suppressor miRNAs, such as miR-124a and miR-127, causing the 
corresponding repression of their oncogenic targets. Although the successful delivery of 
siRNAs to solid tumors has yet to be achieved, designing small-molecule siRNAs to mimic 
tumor-suppressor miRNAs could be a potential method to selectively repress the expression 
of oncogenes (Leu et al., 2003; Saito et al., 2006). 
In the next decade, with the availability of gene profiling databases of epigenetic modifiers, 
it is expected that epigenetic therapy will be translated from the bench to the clinical arena 
and become a real alternative to conventional cancer treatments (Rodríguez-Paredes & 
Esteller, 2011; Zhang et al., 2006). 
In summary, the field of epigenetic biomarker studies is still new but shows promise in the 
clinical management of cancer. Valuable progress has been made on this end, and the 
combination of existing and newly discovered biomarkers will likely allow for more 
accurate diagnosis. Thus, patients will be able to benefit from this new era of personalized 
medicine, in which biomarkers will allow for direct treatments with more effective 
therapeutic agents. 
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